Relationship between nitric oxide and vasoactive intestinal polypeptide in enteric inhibitory neurotransmission.
Although considerable evidence suggests that NO serves as a neurotransmitter in gastrointestinal muscles, it is unlikely to be the only substance involved in enteric inhibitory neurotransmission. Vasoactive intestinal polypeptide (VIP) is known to be expressed by inhibitory motor neurons in the gut, and it appears to be co-localized with nitric oxide synthase (NOS) in a subpopulation of enteric neurons. These data suggest that NO and VIP may be parallel neurotransmitters. Others have suggested that VIP is the primary inhibitory transmitter, and it stimulates production of NO in smooth muscle cells. In this "serial cascade" model NO is a paracrine substance. We performed experiments on circular muscles and cells from the canine proximal colon to further test the idea that NO and VIP are parallel neurotransmitters and to determine the validity of the serial cascade model in these muscles. We found that NO-independent inhibitory effects were unmasked when excitatory and NO-dependent inhibitory responses were blocked. NO-independent inhibitory effects were reduced by alpha-chymotrypsin and blocked by tetrodotoxin. NOS- and VIP-like immunoreactivities were co-localized in enteric neurons and varicose fibers in the circular muscle layer. Similar to several other reports we found no evidence for a constitutive NOS in smooth muscle cells. Several aspects of the serial cascade model were not supported by our results: (i) the electrical and mechanical effects of VIP did not depend upon NO synthesis; (ii) VIP-induced changes in [Ca2+]i did not depend upon NO synthesis; and (iii) VIP did not cause the release of NO from canine colonic muscles. These results are consistent with the hypothesis that NO and VIP are co-transmitters, released in parallel from enteric inhibitory nerves.
Keef
K D
KD
Department of Physiology, University of Nevada School of Medicine, Reno, NV 89557.
Shuttleworth
C W
CW
Xue
C
C
Bayguinov
O
O
Publicover
N G
NG
Sanders
K M
KM
D000818:Animals; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology; D004285:Dogs; D004558:Electric Stimulation; D004594:Electrophysiology; D017615:Enteric Nervous System / Q000378:metabolism / Q000502:physiology*; D005260:Female; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008163:Luminescent Measurements; D008297:Male; D008959:Models, Neurological; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects; D009569:Nitric Oxide / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology*; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*
D002121:Calcium Channel Blockers; D009569:Nitric Oxide; D014660:Vasoactive Intestinal Peptide; D002118:Calcium